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The phosphatidylinositol 3-kinase (PI3K)/AKT and RAS
oncogenic signalling modules are frequently mutated in
sporadic human cancer. Although each of these pathways
has been shown to play critical roles in driving tumour
growth and proliferation, their activation in normal human
cells can also promote cell senescence. Although the
mechanisms mediating RAS-induced senescence have been
well characterised, those controlling PI3K/AKT-induced
senescence are poorly understood. Here we show that
PI3K/AKT pathway activation in response to phosphatase
and tensin homolog (PTEN) knockdown, mutant PI3K,
catalytic, a polypeptide (PIK3CA) or activated AKT
expression, promotes accumulation of p53 and p21,
increases cell size and induces senescence-associated
b-galactosidase activity. We demonstrate that AKT-
induced senescence is p53-dependent and is characterised
by mTORC1-dependent regulation of p53 translation and
stabilisation of p53 protein following nucleolar localisa-
tion and inactivation of MDM2. The underlying mechan-
isms of RAS and AKT-induced senescence appear to be
distinct, demonstrating that different mediators of senes-
cence may be deregulated during transformation by
speciﬁc oncogenes. Unlike RAS, AKT promotes rapid
proliferative arrest in the absence of a hyperproliferative
phase or DNA damage, indicating that inactivation of the
senescence response is critical at the early stages of PI3K/
AKT-driven tumourigenesis. Furthermore, our data imply
that chronic activation of AKT signalling provides
selective pressure for the loss of p53 function, consistent
with observations that PTEN or PIK3CA mutations are
signiﬁcantly associated with p53 mutation in a number of
human tumour types. Importantly, the demonstration that
mTORC1 is an essential mediator of AKT-induced
senescence raises the possibility that targeting mTORC1
in tumours with activated PI3K/AKT signalling may exert
unexpected detrimental effects due to inactivation of a
senescence brake on potential cancer-initiating cells.
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Introduction
Activating mutations in the gene encoding a catalytic
subunit of phosphatidylinositol 3-kinase (PI3K), PI3K,
catalytic, a polypeptide (PIK3CA), or inactivating muta-
tions in the negative regulator of PI3K signalling,
phosphatase and tensin homolog (PTEN), account
for approximately 30% of human sporadic tumours
(Luo et al., 2003; Campbell et al., 2004). Furthermore,
hyperactivation of an important mediator of PI3K
signalling, AKT, is observed in a high proportion of
human cancers, including 20–55% of breast cancers,
B60% of lung cancers, B50% of prostate cancers and
40–70% of melanomas (Altomare and Testa, 2005). In
addition to its role in PI3K/PTEN mutation-driven
cancer, AKT acts as a central node in pathways activated
by oncogenic mutation in genes, including those encoding
EGFR, PDGFR, RAS and LKB1 (Hynes and MacDo-
nald, 2009; Solomon and Pearson, 2009). Three homo-
logous AKT isoforms, AKT1/PKBa,A K T 2 / P K B b and
AKT3/PKBg, have distinct and overlapping roles in a
diverse range of fundamental cellular functions considered
hallmarks of cancer when dysregulated, including cell
growth and proliferation, cell survival, migration and
angiogenesis (Hanahan and Weinberg, 2000; Manning
and Cantley, 2007). AKT-dependent control of cell
growth and proliferation is in large part mediated by
mTORC1 regulation of ribosome biogenesis and protein
translation (Shaw and Cantley, 2006; Hannan et al., 2011).
Like the other prototypical oncogenes, RAS and
MYC, PI3K is an important driver of malignant
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tivated in normal cells, all three can result in cell
death, cell cycle arrest or senescence, depending on
cellular context (Lowe et al., 2004; Gorgoulis and
Halazonetis, 2010). Well-established in vitro markers
of oncogene-induced senescence have now been detected
in vivo in humans, including in melanocytic naevi
(Gray-Schopfer et al., 2006) and neuroﬁbromas
(Courtois-Cox et al., 2006). Clearly, oncogene-induced
senescence must be overcome to enable tumour forma-
tion and pharmacological induction of senescence of
tumour cells is being increasingly seen as a mechanism
for therapeutic intervention (Gewirtz et al., 2008;
Ewald et al., 2010; Nardella et al., 2011). Thus,
understanding the basis of senescence induced by
individual oncogenes in normal cells and how this
process is subverted in cancer cells is critical to our
understanding of malignant transformation and how it
can be effectively targeted.
The paradigm for oncogene-induced senescence was
established by examining the growth arrest of non-
transformed human and mouse cells in response to
activated alleles of the RAS superfamily (Serrano et al.,
1997). In the case of activated RAS, cells undergo an
initial hyperproliferative phase (Tremain et al., 2000)
that is later followed by an irreversible proliferation
arrest (senescence) associated with the accumulation of
cell cycle inhibitors p53, p21 and p16 and larger
ﬂattened cell morphology (Serrano et al., 1997). The
mechanisms contributing to the RAS-induced accumu-
lation of p53 include increased protein stability follow-
ing activation of DNA damage response (Di Micco
et al., 2006; Mallette et al., 2007), p38MAPK (Wang
et al., 2002) and accumulation of promyelocytic
leukemia protein (PML) (Ferbeyre et al., 2000).
Elevated p53 translation also contributes to the senes-
cence phenotype induced by RAS (Bellodi et al., 2010).
Deletion of p53 in mouse cells is sufﬁcient to rescue
RAS-induced proliferation arrest (Serrano et al., 1997);
however; this is not the case in human cells where the
p16 pathway is the prominent effector for proliferation
arrest (Brookes et al., 2002; Huot et al., 2002).
Multiple lines of evidence indicate that increased
PI3K/AKT signalling also induces cell senescence. Loss
of PTEN, the major negative regulator of the PI3K/
AKT pathway, induces senescence in mouse embryonic
ﬁbroblasts (Chen et al., 2005) and mouse prostate
epithelium (Chen et al., 2005; Alimonti et al., 2010a).
PTEN deletion also induces loss of mouse hematopoie-
tic stem cells by induction of the senescence effectors
p53, p21 and p19Arf (Yilmaz et al., 2006; Zhang et al.,
2006). Expression of constitutively active AKT induces
senescence in human endothelial cells (Miyauchi et al.,
2004), mouse embryonic ﬁbroblasts (Chen et al., 2005;
Mavrakis et al., 2008; Nogueira et al., 2008) and mouse
primary keratinocytes (Moral et al., 2009). The mechan-
isms underlying induction of senescence by AKT are
poorly deﬁned, although the accumulation of reactive
oxygen species has been implicated as playing a role
(Nogueira et al., 2008). A better understanding of the
mechanisms of PI3K/AKT-induced senescence will be
crucial for understanding the role of dysregulated PI3K/
AKT signalling in cancer.
To this end, we have analysed PI3K/AKT pathway
activation-induced senescence in a normal human
ﬁbroblast model. We show that this senescence requires
mTORC1-dependent accumulation of p53 involving
increased p53 synthesis and stabilisation mediated by
inactivation of MDM2. We have identiﬁed important
differences between senescence induced by the AKT and
RAS oncogenic modules. Activated PI3K/AKT signal-
ling rapidly induces senescence independent of the
hyperproliferative phase required for the effect of H-
RAS
V12. Consistent with this ﬁnding, PI3K/AKT-
induced senescence is independent of the DNA damage
response that is required by H-RAS
V12.
Results
Hyperactivation of the PI3K/AKT pathway induces
senescence in BJ-T cells
We utilised the well-characterised BJ human ﬁbroblasts
immortalised with human telomerase reverse transcrip-
tase (BJ-T cells) (Hahn et al., 1999) as a model to study
the mechanisms of PI3K-induced responses in non-
transformed human ﬁbroblasts. BJ-T cells were trans-
duced with expression constructs encoding PTEN short
hairpin RNA (shRNA) or the PI3K catalytic subunit
mutant PIK3CA
E545K (Zhao et al., 2005), which is
commonly detected in multiple cancer types and
enhances PI3K/AKT pathway signalling (Campbell
et al., 2004; Samuels et al., 2005). Cells with depleted
PTEN protein levels or expressing PIK3CA
E545K exhib-
ited increased levels of phospho-AKT and phospho-
rylation of the AKT substrate PRAS40 (proline-rich
Akt substrate of 40kDa) demonstrating PI3K pathway
activation and consistent with a previous report (Kim
et al., 2007) accumulation of cell cycle inhibitors p53
and its target p21 (Figure 1a). Cells expressing PTEN
shRNA or PIK3CA
E545K also exhibited a signiﬁcant
increase in cell size (Figure 1b) and senescence-
associated b-galactosidase activity (SAbGAL) (Figure 1c).
These results indicate that activation of PI3K activity
induces multiple markers of senescence in the BJ-T
human ﬁbroblasts.
AKT is a major effector of the PI3K signalling
pathway in cancer (Altomare and Testa, 2005; Franke,
2008). To examine its role in the pro-senescence
response, we expressed constitutively active myristoy-
lated AKT isoforms, myr-AKT1, myr-AKT2 and myr-
AKT3, in BJ-T cells to test whether activation of AKT
alone is sufﬁcient to drive senescence. Each AKT
isoform was examined as they exhibit overlapping but
distinct roles in speciﬁc tumour types (Altomare and
Testa, 2005; Cristiano et al., 2006). BJ-T cells were
also transduced with H-RAS
V12, to allow direct compar-
ison with the prototypical oncogene that activates
senescence pathways in non-transformed cells (Serrano
et al., 1997). Western blot analysis conﬁrmed the
expression of hemagglutinin-tagged myr-AKT isoforms
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V12 (Figure 2a), and increased downstream
signalling as indicated by elevated phosphorylation of
AKT substrates GSK3b and PRAS40. The RAS/
MAPK pathway was upregulated in H-RAS
V12-expres-
sing cells as demonstrated by increased levels of
phospho-ERK1/2. myr-AKT-expressing cells exhibited
increased p53 levels and induction of p21, but only
modest increases in p16 in comparison to activated
RAS.
Cells were analysed for the accumulation of senes-
cence markers at days 10–11 post-transduction to enable
direct comparison with H-RAS
V12, which induces
SAbGAL activity between days 6 and 11 post-transduc-
tion (Serrano et al., 1997; Tremain et al., 2000; Young
et al., 2009). Cells expressing activated AKT isoforms
and H-RAS
V12 showed a signiﬁcant increase in SAbGAL
(Figure 2b) and cell size (Figure 2c), indicating that
AKT activation is sufﬁcient to induce cellular senes-
cence. The formation of senescence-associated hetero-
chromatic foci (SAHF), a marker of RAS- and DNA
damage-induced senescence, is dependent on the p16
pathway (Narita et al., 2003). Consistent with only a
modest accumulation of p16, SAHF formation, as
detected by 40,6-diamidino-2-phenylindole (DAPI)
staining, was not observed in myr-AKT1-expressing
cells (or myr-AKT2/3-expressing cells, data not shown)
unlike the robust induction observed with activated
RAS (Figure 2d).
myr-AKT1 expression was also capable of inducing
senescence in IMR90 cells, an alternative normal human
ﬁbroblast model that is wild type for human telomerase
reverse transcriptase (Ouellette et al., 1999; Gorbunova
et al., 2002). Western blot analysis conﬁrmed the expres-
sion of hemagglutinin-tagged myr-AKT1 and H-RAS
V12,
and increased downstream signalling as indicated by
elevated phosphorylation of AKT substrates GSK3b and
PRAS40, and the RAS target, ERK1/2 (Supplementary
Figure 1A). IMR90 cells expressing activated AKT1 and
RAS exhibited B60% senescent cells as detected by
SAbGAL staining (Supplementary Figure 1B), and as
with BJ-T cells, this was associated with increased p21
expression (Supplementary Figure 1A). IMR90 cells
express higher basal levels of p16 (Beausejour et al.,
2003), and therefore may have a greater propensity for
SAHF formation than BJ-T cells. In IMR90 cells, myr-
AKT1 does moderately induce p16 levels (Supplementary
Figure 1A); however, myr-AKT1 expression failed to
induce SAHF formation in these cells, unlike H-RAS
V12
(Supplementary Figure 1C), suggesting that AKT1-
induced senescence is largely independent of p16.
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Figure 1 PTEN depletion or PIK3CA mutant expression induces senescence in BJ-T cells. (a) BJ-T cells were transduced with pGIPZ-
NS-shRNA or pGIPZ-PTEN-shRNA lentivirus or pBABE or pBABE-PIK3CA
E545K retrovirus. Lysates of these cells were collected
and immunoblotted with the indicated antibodies. Actin is used as a loading control. (b) BJ-T cells as above at day 10 post-
transduction were trypsinised and analysed on a Coulter counter to obtain cell size measurements (cell volume in fL) (n¼4, bars
represent mean±s.e.m., *Po0.05, **Po0.01). (c) Cells as above were ﬁxed and incubated with SAbGAL staining solution overnight.
Cells were washed, stained with DAPI and imaged for both SAbGAL and the number of nuclei. Percentage of SAbGAL-positive cells
was determined for a minimum of 10 low-power magniﬁcation ﬁelds (n¼4–5, bars represent mean±s.e.m., *Po0.05).
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OncogeneTo further compare AKT- and RAS-induced senes-
cence, we examined the time courses of the response of
BJ-T cells to the expression of myr-AKT1 and H-
RAS
V12. Analysis of cell proliferation from days 4 to 9
post-transduction, directly following puromycin selec-
tion, revealed that myr-AKT1-expressing cells exhibited
markedly reduced proliferation at these early time
points (Figure 2e) as did myr-AKT2/3-expressing cells
(data not shown). H-RAS
V12-expressing cells exhibited
comparable proliferation to pBABE control cells at all
time points.
We next compared the SAbGAL levels and the p53,
p21 and p16 responses to the expression of myr-AKT1
and H-RAS
V12 at multiple time points (Supplementary
Figure 2). myr-AKT1 expression induced a more rapid
and complete induction of senescence than H-RAS
V12 up
to 11 days post-retroviral infection (Supplementary
Figure 2A). At early time points following transduction
(days 5 and 8), p21 expression increased rapidly in
AKT-expressing cells (Supplementary Figure 2B),
whereas no increase was observed in RAS-expressing
cells until day 10 (Figure 2a) and day 12 (Supplementary
Figure 2B). Despite the incomplete senescence response
of the H-RAS
V12-expressing population (30–40% of cells
positive for SAbGAL activity), we observed robust p16
induction at days 10–12 in these cells; however, we did
not detect major p16 increases in the myr-AKT-
expressing BJ-T cells.
The late induction of p21 and p16 upon expression of
H-RAS
V12 is consistent with RAS-induced senescence
being associated with an initial proliferative phase and
consequent DNA damage resulting in senescence
(Tremain et al., 2000; Di Micco et al., 2006). Conversely,
we found that AKT rapidly induced proliferative
arrest (Figure 2e) and did not require an initial
proliferative phase to promote senescence (Supplemen-
tary Figure 2A), and therefore we examined whether
expression of activated AKT-induced markers of DNA
damage (Figure 3). Activated AKT expression did not
affect the percentage of cells exhibiting phospho-
gH2A.X foci (Figure 3a) and phosphorylation of p53
at serine 15, an indicator of ATM activation and
downstream CHK2-mediated p53 stabilisation (Banin
et al., 1998; Hirao et al., 2000) (Figure 3b). On the other
hand, H-RAS
V12 expression signiﬁcantly increased both
markers of the DNA damage response. Taken together,
these data identify clear differences between classical
RAS-induced senescence and that mediated by activated
AKT that is rapid and not associated with SAHF
formation or DNA damage.
myr-AKT induces a senescence-associated secretory
phenotype
To further characterise the AKT-induced senescence
phenotype, we examined whether, like H-RAS
V12
(Acosta et al., 2008; Coppe ´ et al., 2008), constitutively
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Figure 2 Activated AKT isoforms induce markers of senescence and proliferation arrest in BJ-T cells. (a) BJ-T cells were transduced
with pBABE, pBABE-myr-AKT isoforms or pBABE-H-RAS
V12. At day 10 post-transduction, cells were harvested and lysates
immunoblotted with the indicated antibodies to demonstrate construct expression, activation of downstream signalling pathways and
accumulation of senescence markers. Actin is used as a loading control. Black arrowheads indicate nonspeciﬁc bands from the 12CA5
anti-HA antibody. (b) Cells prepared as in (a) were ﬁxed, incubated with SAbGAL staining solution overnight, and then stained with
DAPI to visualise non-senescent cells and quantitate total cell number. The percentage of senescent cells was quantitated manually
(n¼4, bars represent mean±s.e.m., **Po0.05, ***Po0.001). (c) BJ-T cells as above were trypsinised and analysed on a Coulter
counter to determine cell size measurements (fL) (n¼6, bars represent mean±s.e.m., *Po0.01, **Po0.05, ***Po0.001). (d)T o
visualise SAHFs, BJ-T cells expressing myr-AKT1 of H-RAS
V12 at day 10 post-transduction were stained with DAPI and imaged using
confocal microscopy. Scale bar represents 10mm. (e) Proliferation of BJ-T cells expressing myr-AKT1 or H-RAS
V12. At 4 days post-
transduction, cells were plated at equal cell number and harvested daily for cell counting on a Coulter counter over a period of 5 days
(n¼5, error bars represent mean±s.e.m.).
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Oncogeneactive AKT could initiate a ‘senescence-associated
secretory phenotype’ or ‘SASP’, where cells markedly
increase the secretion of a number of proinﬂammatory
cytokines. The role of this SASP has not been well
delineated; however, it may function in an autocrine
manner to reinforce growth arrest and also promote
immune system-mediated clearance of senescent cells
(Freund et al., 2010). Most commonly associated with
the SASP is the upregulation of interleukin-6 (IL-6),
IL-8 (Acosta et al., 2008; Coppe ´ et al., 2008; Rodier
et al., 2009), and importantly IL-1a, which can mediate
a positive feedback loop, resulting in the induction of
itself, IL-6 and IL-8 (Orjalo et al., 2009).
As all three AKT isoforms potently induced senes-
cence, continuing analyses focused on the most widely
expressed AKT1 isoform. Real-time PCR (RT–PCR) of
known SASP factors conﬁrmed that expression of IL-1a
and IL-1b was upregulated in cells expressing myr-
AKT1 (Figure 4a). Expression of H-RAS
V12 also
induced IL-1a and IL-1b as described previously (Coppe ´
et al., 2008), although to different levels than that
observed with AKT. Surprisingly, IL-6 mRNA was
reduced in cells expressing myr-AKT1 or H-RAS
V12,
whereas IL-8 was only signiﬁcantly upregulated in H-
RAS
V12-expressing cells. To further investigate this lack
of IL-6 induction, we determined the levels of secreted
IL-1a,I L - 1 b, IL-6 and IL-8 released into the media from
cells expressing myr-AKT1 or H-RAS
V12 at day 10 post-
transduction. The relative levels of secreted IL-1a, IL-1b
and IL-8 induced by myr-AKT1 and H-RAS
V12
(Figure 4b) reﬂected the mRNA expression data
(Figure 4a). Furthermore, despite the paradoxically
decreased IL-6 mRNA levels detected following myr-
AKT1 or H-RAS
V12 expression, IL-6 protein levels
secreted into the media were elevated fourfold, consis-
tent with published data showing that secreted IL-6
is a major contributor to SASP (Coppe ´ et al., 2008).
Although the basis of this discrepancy is unclear, IL-6
expression has been reported to be subjected to post-
transcriptional regulation, including via miR-365- and
mTOR-dependent regulation of IL-6 translation (Narita
et al., 2011; Xu et al., 2011). Thus, AKT-induced
senescence is characterised by an SASP, with increased
secretion of IL-1a, IL-1b, IL-6 and IL-8.
myr-AKT-induced senescence is p53-dependent
In human ﬁbroblasts, the proliferation arrest induced by
activated RAS cannot be rescued by the inhibition of
p53 activity alone (Serrano et al., 1997); however, it is
dependent on the presence of functional p16 (Brookes
et al., 2002; Huot et al., 2002). Given the absence of
signiﬁcant p16 pathway activation and the clear
differences observed between H-RAS
V12- and myr-
AKT1-induced senescence, we examined whether
AKT-induced senescence was speciﬁcally dependent on
the p53 pathway.
To determine the contribution of p53 to AKT-
induced senescence, we examined the induction of
senescence markers in BJ-T-myr-AKT cells stably
expressing p53 shRNA or a control shRNA. myr-
AKT failed to induce p21 expression in p53 knockdown
cells (Figure 5a) or increase the cell doubling time
and mean cell volume, compared with control cells
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Figure 3 myr-AKT1 fails to induce markers of DNA damage. (a) BJ-T cells transduced with pBABE, pBABE-myr-AKT1 or pBABE-
H-RAS
V12 were immunostained with phospho-Ser139-gH2A.X. Cells were imaged and the percentage that exhibited nuclear phospho-
Ser139-gH2A.X foci was quantitated for a minimum of 200 cells per experiment (n¼3, bars represent mean±s.e.m., ***Po0.001).
(b) Lysates of BJ-T cells expressing pBABE, pBABE-myr-AKT1 or H-RAS
V12 were immunoblotted with phospho-p53(Ser15) and p53
antibodies. Lysate of g-irradiated A549 cells were included as a positive control.
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Oncogeneexpressing myr-AKT and the control shRNA
(Figures 5b and c). SAbGAL positivity was signiﬁcantly
reduced in BJ-T-myr-AKT/p53 stable knockdown
cells as compared with control BJ-T-myr-AKT cells
(Figure 5d). We also determined that AKT could not
induce p21 or SAbGAL activity in BJ-T cells expressing
SV40 large T antigen (Hahn et al., 1999), consistent with
the ability of SV40 large T antigen to repress p53 and
retinoblastoma activity (data not shown).
We also examined the effect of acute p53 knockdown
during induction of myr-AKT1 expression. BJ-T cells
co-expressing p53 shRNA and myr-AKT1 were ana-
lysed for proliferation from day 5 post-transduction,
and for apoptosis markers and the percentage of cells in
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Figure 4 myr-AKT1 expression induces upregulation of senescence-associated secretory factors. (a) RT–PCR analysis of IL-1a,
IL-1b, IL-6, IL-8 and GAPDH expression in BJ-T cells expressing pBABE, myr-AKT1 or H-RAS
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Figure 5 AKT-induced senescence is p53-dependent. (a) BJ-T cells were transduced with retrovirus encoding control or p53 shRNA.
These cell lines were then transduced with MSCV or MSCV-myr-AKT. Lysates were harvested at day 10 post-transduction and
immunoblotted with p53 and p21 antibodies. (b) Control or p53 shRNA expressing BJ-T cell lines transduced with MSCV or MSCV-
myr-AKT. Cells were plated at equal cell number and harvested 3 days later. Cell numbers were used to determine population doubling
time (n¼4, bars represent mean±s.e.m., *Po0.05, **Po0.01). (c) Cells as in (b) were analysed on the Coulter counter to obtain cell
size measurements (n¼3, bars represent mean±s.e.m., **Po0.01, ***Po0.001). (d) Cells as in (b) were analysed for SAbGAL
activity. Cells were imaged under brightﬁeld for SAbGAL- and DAPI-stained nuclei, and the cellular autoﬂuorescence was imaged to
indicate cell morphology. The percentage of cells that stained positive for SAbGAL was determined (n¼4, bars represent
mean±s.e.m., ***Po0.001).
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Oncogenethe S phase at day 10 post-transduction (Supplementary
Figure 3). Acute p53 knockdown, conﬁrmed by
immunoblot analysis (Supplementary Figure 3A), res-
cued the reduced proliferation of myr-AKT1-expressing
cells to that of control cells (Supplementary Figure 3B).
The major effect of p53 knockdown was to increase the
percentage of cells in the S phase (Supplementary Figure
3C), with minimal effect on apoptosis observed by
Annexin V and propidium iodide positivity (Supple-
mentary Figure 3D).
Taken together, these results indicate that p53 knock-
down speciﬁcally regulates the induction of senescence
markers by activated AKT and, unlike the case of H-
RAS
V12 (Serrano et al., 1997), is sufﬁcient to rescue cell
proliferation. These results are intriguing given that
previous reports demonstrate that AKT promotes the
activity of the E3 ubiquitin ligase MDM2 (Ogawara
et al., 2002), the important negative regulator of p53
(Haupt et al., 1997; Kubbutat et al., 1997). Post-
translational modiﬁcations, protein–protein interactions
and/or alterations to cellular localisation of either p53
or MDM2 can block the p53:MDM2 interaction
resulting in p53 stabilisation (Meek and Knippschild,
2003).
To investigate the mechanism by which p53 accumu-
lates in AKT-expressing BJ-T cells, p53 stability was
assessed by [
35S]Met/Cys pulse-chase analysis. Over the
60min chase period, [
35S]Met/Cys-labelled p53 reduced
at a slower rate in myr-AKT cells compared to pBABE
cells, indicating that myr-AKT expression decreased p53
turnover (Figure 6a). Importantly, a 45% increase in
p53 synthesis was observed in the 30min pulse period in
myr-AKT-expressing cells compared with control cells
(Figure 6b), with no change in relative p53 transcript
levels detected (Supplementary Figure 4A). Further-
more, rapid lysis of pBABE- or myr-AKT-expressing
cells plus or minus the proteasome inhibitor MG132
treatment indicated that AKT-expressing cells had
reduced levels of polyubiquitinated p53 in the steady
state (Figure 6c). These results indicate that p53
accumulation in AKT cells results from both a reduction
in MDM2-mediated p53 ubiquitination and degrada-
tion, plus enhanced p53 translation.
Our results are in contrast to previous reports
that AKT phosphorylation of MDM2 promotes its
nuclear localisation (Mayo and Donner, 2001; Mayo
et al., 2002) and enhances MDM2 ubiquitin ligase
activity, resulting in p53 destabilisation (Ogawara et al.,
2002). To determine if the reported AKT/MDM2
pathway is functional in BJ-T cells, we assessed
MDM2 phosphorylation at Ser166 and cellular localisa-
tion. BJ-T cells already express appreciable levels of
MG132
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Figure 6 MDM2 activity is reduced with the expression of AKT. (a) BJ-T cells expressing pBABE or pBABE-myr-AKT1 were
subjected to [
35S]Met/Cys pulse-chase analysis. Lysates were collected at various chase times and p53 immunoprecipitations (IPs)
performed. Complexes were resolved by SDS–PAGE and gels exposed to phosphorimager storage screens. p53 band intensity was
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Oncogenephospho-Ser166-MDM2, but enforced expression of
myr-AKT did not increase these levels any further
(Supplementary Figure 4B). The migration of phospho-
Ser166-MDM2 was altered, suggesting that AKT
may promote alternative post-translational modiﬁca-
tions of MDM2. Fractionation experiments demon-
strated that AKT expression induced a slight increase in
nuclear and cytoplasmic MDM2 levels (Supplementary
Figure 4C).
To investigate why p53 ubiquitination was markedly
reduced despite slightly elevated nuclear MDM2 levels,
we examined MDM2 subnuclear localisation. Nucleolar
accumulation of MDM2 has been reported to be
associated with reduced MDM2 activity (Weber et al.,
1999; Ashcroft et al., 2000), due to its sequestration into
inactive complexes. Confocal analysis revealed a robust
increase in the accumulation of MDM2 in the nucleolus
of AKT-expressing cells (Figure 6d). Next, we examined
if induction of the tumour suppressor ARF contributes
to MDM2 nucleolar localisation. ARF expression can
be induced by oncogenic insult and mediates p53
stabilisation by sequestration of MDM2 in the nucleolus
(Weber et al., 1999). ARF protein could not be detected
in myr-AKT-expressing cells (Supplementary Figure
4D), although it was observed in response to MYC, a
known activator of ARF (Zindy et al., 1998), indicating
that MDM2 nucleolar sequestration is ARF-indepen-
dent. Accumulation of the PML protein has been shown
to contribute to p53 stabilisation (Ferbeyre et al., 2000)
via its nucleolar sequestration (Bernardi et al., 2004).
However, we found no change in the expression levels of
PML or any increase in PML nucleolar localisation in
BJ-T cells expressing AKT as compared with control
cells (data not shown). Taken together, these results
indicate that AKT induces DNA damage-independent
p53 stabilisation via ARF- and PML-independent
nucleolar sequestration of MDM2.
mTORC1 activity is essential for AKT-induced
senescence
mTORC1 is an important mediator of PI3K/AKT
signalling to protein synthesis, cell growth and pro-
liferation (Manning and Cantley, 2007). To determine
the contribution of enhanced mTORC1 signalling to
AKT-induced senescence, BJ-T cells transduced with
myr-AKT or control pBABE were treated with the
mTORC1-selective inhibitor, rapamycin and markers of
senescence analysed. Upon treatment with rapamycin,
the percentage of AKT cells positive for SAbGAL was
signiﬁcantly reduced (Figure 7a). Rapamycin treatment
also dramatically reduced AKT-induced effects on cell
size (Figure 7b), and the SASP (Figure 7c), indicating
that mTORC1 activity is critical for PI3K/AKT-driven
senescence.
Given that we have shown a marked effect of
inhibiting mTORC1- on AKT-induced senescence,
together with the fact that mTORC1 is an important
regulator of protein synthesis (Proud, 2007) and a
previous report links mTORC1 to the regulation of p53
translation rates (Lee et al., 2007), we examined the
effect of rapamycin on the AKT-induced accumulation
of p53. We found that inhibition of mTORC1 by
rapamycin treatment ablated p53 accumulation and the
expression of the p53 effector and transcriptional target
p21 (Figure 7d). This reduction in multiple markers of
senescence with rapamycin did not correspond with an
increase in proliferation (Supplementary Figure 5);
however, this result is expected given the observed
cytostatic effect of rapamycin on ﬁbroblasts transduced
with control pBABE.
Taken together, our data are consistent with a model
where elevated PI3K/AKT signalling to mTORC1 in
non-transformed human ﬁbroblasts leads to increased
p53 synthesis. In combination with MDM2 nucleolar
sequestration and reduced p53 ubiquitination, this
results in the robust accumulation of p53 and cellular
senescence (Figure 8).
Discussion
Oncogene-induced senescence is an important mechan-
ism for protection from tumourigenesis in vivo and
current research suggests that it may be possible to
activate senescence-inducing pathways for cancer ther-
apy (Collado and Serrano, 2010; Lin et al., 2010). Here
we demonstrate that activation of the PI3K/AKT
pathway, one of the most commonly upregulated
signalling modules in human tumours, rapidly induces
senescence in human ﬁbroblasts. We demonstrate
that depletion of p53 levels via shRNA-mediated
knockdown or inhibition of its activity via stable
expression of SV40 large T antigen bypasses the
senescence response. Thus, p53 signalling represents an
important potential barrier to PI3K/AKT-driven tu-
mourigenesis and activation of AKT in normal cells is
likely to provide selective pressure for loss of p53
function. We ﬁnd that AKT enhances both p53
translation and protein stability, and that AKT-induced
p53 accumulation and downstream senescence is depen-
dent on mTORC1 activity.
AKT fails to induce DNA damage
p53- and retinoblastoma-dependent oncogene-induced
senescence has been best characterised in response to
activated RAS signalling in mouse and human ﬁbro-
blasts (Serrano et al., 1997; Ferbeyre et al., 2002), where
increased p53 expression is dependent on an initial
hyperproliferative phase induced by activated RAS
followed by accumulation of DNA damage (Di Micco
et al., 2006; Mallette et al., 2007). Importantly, here we
show that PI3K/AKT-induced senescence proceeds via a
different mechanism to RAS. It occurs rapidly, and is
independent of DNA damage. The rapid cell cycle arrest
induced by AKT hyperactivation implies that these cells
are far less likely to escape senescence than cells with
hyperactivating mutations in RAS; thus, suggesting
that somatic mutations in AKT are unlikely to be
the initial mutation in the multistep progression to
tumourigenesis.
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OncogeneAKT-induced senescence occurs independent of p16
activation of SAHFs
In addition, we demonstrate that, unlike RAS, AKT fails
to induce high levels of p16 or SAHFs in either BJ-T or
IMR90 cells. Although the levels of p16 have been shown
to be an important determinant for RAS-induced
senescence (Benanti and Galloway, 2004), our data
indicate that p16 is unlikely to play a role in AKT-
induced senescence. Rapid induction of senescence with-
out signs of DNA damage, p16 accumulation or SAHF
formation has similarly been reported for the oncogenic
fusion protein RUNX1-ETO (Wolyniec et al., 2009). The
p16-dependent alterations to chromatin structure, de-
tected as SAHFs, are thought to promote the irreversi-
bility of the cell cycle arrest due to stable silencing of pro-
proliferative genes (Narita et al., 2003). It is not clear as
to how the absence of SAHFs would affect the
maintenance of the senescence phenotype of AKT cells
in vivo. However, here we demonstrate that both AKT
and RAS induce a robust senescence-associated secretory
phenotype, which may function to maintain senescence
(Freund et al., 2010). Identiﬁcation of these distinctly
different mechanisms for p53-dependent senescence
induction by active RAS and AKT reinforce the concept
that speciﬁc oncogenic signalling modules may target
distinct mediators of senescence.
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Figure 7 AKT-induced senescence is dependent on mTORC1 activity. (a) BJ-T cells were transduced with pBABE or pBABE-myr-
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Figure 8 Proposed mechanism of AKT-induced senescence.
(a) Physiological levels of AKT signalling lead to the activation
of MDM2 at levels that maintain low p53 protein expression.
(b) Chronic hyperactivation of AKT results in mTORC1-depen-
dent increases in p53 translation and simultaneously stimulates
MDM2 sequestration within the nucleolus, inhibiting p53 ubiqui-
tination to further enhance p53 accumulation leading to cellular
senescence.
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OncogeneAKT induces senescence via post-transcriptional
regulation of p53
Activated PI3K/AKT signalling results in marked
stabilisation of p53 protein. This was unexpected given
that AKT has been reported to promote the activity of
the E3 ubiquitin ligase MDM2, the important negative
regulator of p53 (Haupt et al., 1997; Kubbutat et al.,
1997). However, in human ﬁbroblasts, we found that
active AKT signalling reduces p53 ubiquitination and
this corresponds to increased nucleolar sequestration,
and hence inactivation of MDM2. Our data indicate
that this nucleolar sequestration is independent of ARF
and PML, and thus is likely to involve binding to other
proteins, which localise to the nucleolus either constitu-
tively or under conditions of stress such as nucleophos-
min (Kurki et al., 2004) and multiple ribosomal
proteins, including RPL5, RPL11 and RPL23 (Lohrum
et al., 2003; Bhat et al., 2004; Dai and Lu, 2004; Dai
et al., 2004). These binding events are invariably
associated with p53 stabilisation (Zhang and Lu,
2009). It is tempting to hypothesise that while transient
activation of AKT by growth factors can lead to active
MDM2, p53 degradation and cell survival, chronic
activation of the pathway, such as that following
oncogenic mutation within the signalling network,
results in nucleolar sequestration and inactivation of
MDM2, and accumulation of p53 with a subsequent
induction of senescence.
PI3K/AKT pathway activation and p53 alterations
cooperate in human cancer
Consistent with p53-induced senescence acting as a
major ‘brake’ for PI3K/AKT-driven human cancer,
mutational analysis of primary human tumours has
demonstrated signiﬁcant associations between PTEN or
PIK3CA, and p53 alterations in colorectal cancer
(Nosho et al., 2008), gastric cancer (Oki et al., 2005),
non-small-cell lung cancer (Andjelkovic et al., 2011) and
bladder cancer (Puzio-Kuter et al., 2009). Furthermore,
concomitant alterations in these pathways often result in
poor patient outcome (Catasus et al., 2009; Puzio-Kuter
et al., 2009; Andjelkovic et al., 2011). These reports,
together with our data, raise concerns for the rational
design of pro-senescence therapies to combat cancers
driven by activating mutations in the PI3K/AKT
signalling network, as aggressive tumours will com-
monly have previously subverted p53 signalling.
In this context, therapeutic activation of p53-indepen-
dent pro-senescence pathways will thus be required,
such as targeting the E3 ligase Skp2, which acts via
regulation of p21, p27 and Atf4 (Lin et al., 2010), or
inducing p16.
mTORC1 inhibitors prevent AKT-induced senescence:
implications for cancer therapy
Importantly, our results demonstrate that mTORC1 is
the critical mediator of induction of p53-dependent
senescence by AKT in non-transformed human ﬁbro-
blasts. Treatment of cells expressing active AKT with
the allosteric mTORC1 inhibitor rapamycin reduced
p53 and p21 to control levels and prevented senescence.
Previous reports indicate that mTORC1 activation
downstream of AKT will promote p53 accumulation
via regulation of p53 translation as in PTEN
 / 
(Alimonti et al., 2010b) and Tsc1
 /  mouse embryonic
ﬁbroblasts, (Lee et al., 2007). Our results in human cells
are also consistent with the emerging idea that the levels
of mTORC1 activity determine the outcome of p53
activation in cells, where low mTORC1 activity in the
context of genotoxic stress or MDM2 activation favours
cellular quiescence over senescence (Korotchkina et al.,
2010; Leontieva and Blagosklonny, 2010).
The dependence of AKT-induced senescence on
mTORC1 activity has direct implications for the use
of mTORC1 inhibitors as anticancer agents. Inhibitors
such as RAD001 and CCI-779 have delivered limited
therapeutic beneﬁt as single agents (Brachmann et al.,
2009). This lack of effect has been attributed, at
least in part, to the inactivation of mTORC1-dependent
negative feedback of PI3K/AKT signalling (O’Reilly
et al., 2006) and/or the activity of the RAS pathway
(Carracedo et al., 2008). Our data provide another
level of potential concern where mTORC1 inhibition
may relieve the senescence ‘brake’ in p53 wild-type
cells and promote PI3K-dependent transformation.
Targeted therapies are now being designed and tested
that will alleviate the pro-tumourigenic effects of
mTORC1 inhibition. These include mTOR active site
inhibitors that will target both mTORC2-dependent
AKT activation and mTORC1-dependent growth (Feld-
man et al., 2009; Dowling et al., 2010; Hsieh et al.,
2010), dual PI3K/mTOR inhibitors (Bhatt et al., 2010)
or the use of the MDM2 antagonist Nutlin-3a in
combination with mTOR inhibition (Alimonti et al.,
2010b).
In summary, we demonstrate that constitutive PI3K/
AKT pathway activation in normal human cells results
in the accumulation of p53 and rapid induction of
cellular senescence. Consequently, inactivation of the
senescence response is likely to be critical at the early
stages of PI3K/AKT-driven tumourigenesis, and con-
sistent with this model, PTEN or PIK3CA mutations
are signiﬁcantly associated with p53 mutation in human
tumours. Importantly, we demonstrate that mTORC1 is
an essential mediator of AKT-induced senescence,
providing further insight to aid in the rational design
of cancer therapeutic strategies to target tumors with
dysregulated PI3K/AKT signalling.
Materials and methods
Plasmid constructs
Murine stem cell virus (MSCV) plasmids encoding myr-AKT
isoforms are as described previously (Chan et al., 2011).
pBABE-puro, pBABE-puro-myr-AKT2, pBABE-puro-myr-
AKT3 and pBABE-puro-PIK3CA
E545K were from Addgene
Inc. (Cambridge, MA, USA). pBABE-myr-AKT1 was directly
subcloned from MSCV-myr-AKT1. pBABE-puro-H-RAS
V12
was a gift from Patrick Humbert (Peter MacCallum Cancer
Centre, Melbourne, VIC, Australia). pGIPZ-PTEN shRNA and
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OncogenepGIPZ-NS shRNA were from Open Biosystems (Huntsville,
AL, USA).
Cell lines
BJ-T cells, a gift from Robert Weinberg, and derivatives were
cultured in Dulbecco’s modiﬁed Eagle’s medium:M199 media
at a ratio of 4:1 (v/v) with 15% fetal calf serum and 2mM
L-glutamine (Hahn et al., 1999, 2002) and maintained in 5%
CO2 at 371C. Cells expressing pBABE or MSCV constructs
were enriched by puromycin selection (1mg/ml) (Sigma-
Aldrich, St Louis, MO, USA) or ﬂuorescence-activated cell
sorter, respectively. Rapamycin (20nM) (Calbiochem, Gibbs-
town, NJ, USA) was added 1 day following infection and
replaced every two days.
Western blotting and antibodies
Cells were lysed in western solubilisation buffer (0.5mM
EDTA, 20mM HEPES (pH7.9), 2% sodium dodecyl sulfate
(SDS)). Lysates were mechanically sheared and a DC assay
(BioRad, Hercules, CA, USA) utilised for protein concentra-
tion determination. Proteins were visualised using horse radish
peroxidase-conjugated secondary antibodies (BioRad) and
Western Lightening Chemiluminescence Plus (Perkin-Elmer,
Covina, CA, USA). MDM2 (SMP14), p16, p21 (C-19), p53
(DO-1) and H-RAS antibodies were from Santa Cruz
Technology (Santa Cruz, CA, USA). Actin and phospho-
Ser139-gH2A.X antibody were from Millipore (Billerica, MA,
USA). Fibrillarin antibodies were from Abcam (Cambridge,
MA, USA). The 12CA5 (HA-tag) antibody was puriﬁed in-
house. All other antibodies were from Cell Signalling
Technology (Beverly, MA, USA).
SAbGAL staining
Cells were stained for SAbGAL as described previously
(Debacq-Chainiaux et al., 2009) and co-stained with DAPI
(Molecular Probes, Invitrogen, Carlsbad, CA, USA), before
imaging on a Olympus BX-51 or BX-61 microscope (Olympus
America Inc., Center Valley, PA, USA), or a Cellomics
imaging platform (Thermo Fisher Scientiﬁc, Waltham, MA,
USA). SAbGAL cells and total nuclei were counted manually
using the public domain ImageJ software (NIH, Bethesda,
MD, USA; Abramoff et al., 2004).
Immunoﬂuorescence
For phospho-Ser139-gH2A.X, staining cells were ﬁxed in 95%
ethanol/5% acetic acid, permeabilised in 0.1% Tx-100/
phosphate-buffered saline for 2min and blocked for 30min
in 3% bovine serum albumin/phosphate-buffered saline. For
MDM2/ﬁbrillarin co-staining, cells were ﬁxed in methanol for
5min at  201C and blocked with 5% goat serum/phosphate-
buffered saline for 30min. Antibodies were diluted in blocking
buffer and incubated with cells for 1h. Cells were imaged on
an Olympus BX51 epiﬂuorescence or Leica SP5 confocal
microscope (Leica, Wetzlar, Germany). Quantitation of
relative nucleolar MDM2 localisation was performed using
MetaMorph (Molecular Devices, Sunnyvale, CA, USA).
RNA extraction and RT–PCR
RNA was extracted using an RNA extraction kit (Bioline,
Alexandria, NSW, Australia).
32P-labelled riboprobe was
added to samples before column puriﬁcation to allow RNA
recovery calculation. RNA was normalised for cell number for
cDNA production using random hexamers primers (Promega,
Madison, WI, USA) and Superscript III (Invitrogen). Primer
sequences are listed in Supplementary information.
Cytokine bead array for the analysis of IL secretion
Cells were plated at 50000–100000 in 150ml of media per well
of a 96-well plate. After 24h, the media were removed, cleared
by centrifugation and stored at  801C. The level of secreted
IL-1a, IL-b, IL-6 and IL-8 was determined using a custom-
made Millipore Milliplex Human Cytokine Multiplex Immu-
noassay Kit following the manufacturer’s instructions.
p53 pulse-chase analysis
Cells were incubated in Cys- and Met-free Dulbecco’s modiﬁed
Eagle’s medium containing 15% fetal calf serum for 1h, and
then 200mCi Express
35S Protein Labelling Mix (Perkin-Elmer)
was added for 30min. Cells were washed with media, and
incubated for the designated periods and harvested (50mM
Tris (pH 8.0), 150mM NaCl, 5mM EDTA, 0.5% NP-40,
complete protease inhibitors; Roche Applied Science, Castle
Hill, NSW, Australia). P53 was immunoprecipitated using p53
antibody (0.3mg) and Protein A-Sepharose (Amersham
Biosciences, Piscataway, NJ, USA). Following washes, sam-
ples were run on SDS–polyacrylamide gel electrophoresis
(PAGE), gels dried, exposed to a Phosphorimager screen and
imaged on a Typhoon (GE Healthcare).
Statistical analysis
All statistical tests were performed in GraphPad Prism
(GraphPad Software Inc., La Jolla, CA, USA). The analysis
was performed using paired t-tests or repeated measures
analysis of variance with Bonferroni post-test.
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